Receptor-selective changes in μ-, δ- and κ-opioid receptors after chronic naltrexone treatment in mice

European Journal of Neuroscience

Volumn 17, Issue 5, 2003, Pages 1006-1012

  Lesscher, Heidi M B ^a   Bailey, Alexis ^b   Burbach, J Peter H ^a   Van Ree, Jan M ^a   Kitchen, Ian ^b   Gerrits, Mirjam A F M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Autoradiography; Mice; Naltrexone; Opioid; Receptor; Regulation

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALTREXONE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

ANIMALS; AUTORADIOGRAPHY; BRAIN; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 0345701343     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2003.02502.x     Document Type: Article

References (35)

1. Bardo, M.T. & Neisewander, J.L. (1987) Chronic naltrexone supersensitizes the reinforcing and locomotor-activating effects of morphine. Pharmacol. Biochem. Behav., 28, 267-273.
2. Castelli, M.P., Melis, M., Mameli, M., Fadda, P., Diaz, G. & Gessa, G.L. (1997) Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain. Brain Res. Mol. Brain Res., 45, 149-153.
3. Cote, T.E., Izenwasser, S. & Weems, H.B. (1993) Naltrexone-induced upregulation of mu opioid receptors on 7315c cell and brain membranes: enhancement of opioid efficacy in inhibiting adenylyl cyclase. J. Pharmacol. Exp. Ther., 267, 238-244.
4. Danks, J.A., Tortella, F.C., Long, J.B., Bykov, V., Jacobson, A.E., Rice, K.C., Holaday, J.W. & Rothman, R.B. (1988) Chronic administration of morphine and naltrexone up-regulate[3H][D-Ala2,D-leu5]enkephalin binding sites by different mechanisms. Neuropharmacology, 27, 965-974.
5. Di Chiara, G. & Imperato, A. (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther., 244, 1067-1080.
6. Diaz, A., Pazos, A., Florez, J., Ayesta, F.J., Santana, V. & Hurle, M.A. (2002) Regulation of μ-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience, 112, 345-353.
7. Duttaroy, A., Shen, J., Shah, S., Chen, B., Sehba, F., Carroll, J. & Yoburn, B.C. (1999) Opioid receptor upregulation in mu-opioid receptor deficient CXBK and outbred Swiss Webster mice. Life Sci., 65, 113-123.
8. Giordano, A.L., Nock, B. & Cicero, T.J. (1990) Antagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu and delta opioid receptors. J. Pharmacol. Exp. Ther., 255, 536-540.
9. Gutstein, H. & Akil, H. (2001) Opioid Analgesics. In Hardman, J.G., Limbird, L.E. & Goodman Gilman, A. (Eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, pp. 569-621.
10. Jenab, S., Kest, B. & Inturrisi, C.E. (1995) Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment. Brain Res., 691, 69-75.
11. Kest, B., Lee, C.E., Jenab, S., Kao, B. & Inturrisi, C.E. (1998) Chronic naltrexone differentially affects supraspinal delta-opioid receptor-mediated antinociception. Eur. J. Pharmacol., 345, 47-53.
12. Kieffer, B.L. (1995) Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol. Neurobiol., 15, 615-635.
13. Kieffer, B.L. & Gaveriaux-Ruff, C. (2002) Exploring the opioid system by gene knockout. Prog. Neurobiol., 66, 285-306.
14. Kitchen, I., Slowe, S.J., Matthes, H.W. & Kieffer, B. (1997) Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res., 778, 73-88.
15. Kreek, M.J., LaForge, K.S. & Butelman, E. (2002) Pharmacotherapy of addictions. Nat. Rev. Drug Discov., 1, 710-726.
16. Morris, B.J., Millan, M.J. & Herz, A. (1988) Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography. J. Pharmacol. Exp. Ther., 247, 729-736.
17. Narita, M., Funada, M. & Suzuki, T. (2001) Regulations of opioid dependence by opioid receptor types. Pharmacol. Ther., 89, 1-15.
18. Pan, Z.Z. (1998) mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol. Sci., 19, 94-98.
19. Paxinos, G. & Franklin, K.B.J. (2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
20. Ramsey, N.F. & Van Ree, J.M. (1990) Chronic pretreatment with naltrexone facilitates acquisition of intravenous cocaine self-administration in rats. Eur. Neuropsychopharmacol., 1, 55-61.
21. Rothman, R.B., Bykov, V., Long, J.B., Brady, L.S., Jacobson, A.E., Rice, K.C. & Holaday, J.W. (1989) Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-o15]enkephalin: further evidence for two mu-binding sites. Eur. J. Pharmacol., 160, 71-82.
22. Rubino, T., Massi, P., Patrini, G., Venier, I., Giagnoni, G. & Parolaro, D. (1994) Effect of chronic exposure to naltrexone and opioid selective agonists on G protein mRNA levels in the rat nervous system. Brain Res. Mol. Brain Res., 23, 333-337.
23. Schenk, S. & Nawiesniak, E. (1985) Chronic naltrexone treatment increases the heroin-produced facilitation of self-stimulation. Pharmacol. Biochem. Behav., 22, 175-177.
24. Tempel, A., Gardner, E.L. & Zukin, R.S. (1984) Visualization of opiate receptor upregulation by light microscopy autoradiography. Proc. Natl. Acad. Sci. USA, 81, 3893-3897.
25. Tempel, A., Gardner, E.L. & Zukin, R.S. (1985) Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J. Pharmacol. Exp. Ther., 232, 439-444.
26. Tempel, A., Zukin, R.S. & Gardner, E.L. (1982) Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci., 31, 1401-1404.
27. Unterwald, E.M., Anton, B., To, T., Lam, H. & Evans, C.J. (1998) Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone. Neuroscience, 85, 897-905.
28. Unterwald, E.M., Rubenfeld, J.M., Imai, Y., Wang, J.B., Uhl, G.R. & Kreek, M.J. (1995) Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Brain Res. Mol. Brain Res., 33, 351-355.
29. Van Ree, J.M., Gerrits, M.A. & Vanderschuren, L.J. (1999) Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol. Rev., 51, 341-396.
30. Yoburn, B.C., Cohen, A.H. & Inturrisi, C.E. (1986a) Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. J. Pharmacol. Exp. Ther., 237, 126-130.
31. Yoburn, B.C., Luke, M.C., Pasternak, G.W. & Inturrisi, C.E. (1988) Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci., 43, 1319-1324.
32. Yoburn, B.C., Nunes, F.A., Adler, B., Pasternak, G.W. & Inturrisi, C.E. (1986b) Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse. J. Pharmacol. Exp. Ther., 239, 132-135.
33. Yoburn, B.C., Shah, S., Chan, K., Duttaroy, A. & Davis, T. (1995) Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol. Biochem. Behav., 51, 535-539.
34. Yoburn, B.C., Sierra, V. & Lutfy, K. (1989) Chronic opioid antagonist treatment: assessment of receptor upregulation. Eur. J. Pharmacol., 170, 193-200.
35. Zukin, R.S., Sugarman, J.R., Fitz-Syage, M.L., Gardner, E.L., Zukin, S.R. & Gintzler, A.R. (1982) Naltrexone-induced opiate receptor supersensitivity. Brain Res., 245, 285-292.